在 BIOMED-2 方案中完全检测到基于 FR1 至 FR3 引物的免疫球蛋白重链重排 PCR 模式与弥漫大 B 细胞淋巴瘤患者的不良预后有关

EJHaem Pub Date : 2024-06-18 DOI:10.1002/jha2.921
Tomohiro Yabushita, Yoshimitsu Shimomura, Hayato Maruoka, Daisuke Katoh, Daisuke Yamashita, Hironaga Satake, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Momoko Nishikori, Takeshi Morimoto, Yukihiro Imai, Takayuki Ishikawa
{"title":"在 BIOMED-2 方案中完全检测到基于 FR1 至 FR3 引物的免疫球蛋白重链重排 PCR 模式与弥漫大 B 细胞淋巴瘤患者的不良预后有关","authors":"Tomohiro Yabushita,&nbsp;Yoshimitsu Shimomura,&nbsp;Hayato Maruoka,&nbsp;Daisuke Katoh,&nbsp;Daisuke Yamashita,&nbsp;Hironaga Satake,&nbsp;Nobuhiro Hiramoto,&nbsp;Satoshi Yoshioka,&nbsp;Noboru Yonetani,&nbsp;Momoko Nishikori,&nbsp;Takeshi Morimoto,&nbsp;Yukihiro Imai,&nbsp;Takayuki Ishikawa","doi":"10.1002/jha2.921","DOIUrl":null,"url":null,"abstract":"<p>Somatic hypermutations (SHMs) in the variable region (V<sub>H</sub>) of the immunoglobulin heavy chain (IgH) gene are common in diffuse large B-cell lymphoma (DLBCL). Recently, IgH V<sub>H</sub> SHMs have become known as immunogenic neoantigens, but few studies have evaluated the prognostic impact of the frequency of V<sub>H</sub> SHMs in DLBCL. The BIOMED-2 protocol is the gold standard polymerase chain reaction (PCR) for clonality analysis in lymphoid malignancies, but can produce false negatives due to the presence of IgH V<sub>H</sub> SHMs. To overcome this problem, three primer sets were designed for the three framework regions (FR1, FR2, and FR3). We evaluated the predictive value of this PCR pattern in patients with DLBCL. To evaluate the prognostic impact of complete detection of the clonal amplifications (V<sub>H</sub>FR1–J<sub>H</sub>, V<sub>H</sub>FR2–J<sub>H</sub>, and V<sub>H</sub>FR3–J<sub>H</sub>) in the BIOMED-2 protocol, we retrospectively analyzed 301 DLBCL patients who were initially treated with anthracycline-based immunochemotherapy. Complete detection of the FR1 to FR3 primer-based IgH V<sub>H</sub> PCR patterns in the BIOMED-2 protocol was associated with low frequency of V<sub>H</sub> SHMs (<i>p</i> &lt; 0.001). Patients who were positive for all these three PCRs (<i>n</i> = 79) were significantly associated with shorter 5-year overall survival (OS; 54.2% vs. 73.2%; <i>p</i> = 0.002) and progression-free survival (PFS; 34.3% vs. 59.3%; <i>p</i> &lt; 0.001) compared to patients with other PCR patterns (<i>n</i> = 202). Specifically, the successful FR3-J<sub>H</sub> detection was associated with significantly worse OS (<i>p</i> &lt; 0.001) and PFS (<i>p</i> &lt; 0.001). PCR patterns of complete IgH rearrangement using the BIOMED-2 protocol are clinically meaningful indicators for prognostic stratification of DLBCL patients.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.921","citationCount":"0","resultStr":"{\"title\":\"Complete detection of FR1 to FR3 primer-based PCR patterns of immunoglobulin heavy chain rearrangement in the BIOMED-2 protocol is associated with poor prognosis in patients with diffuse large B-cell lymphoma\",\"authors\":\"Tomohiro Yabushita,&nbsp;Yoshimitsu Shimomura,&nbsp;Hayato Maruoka,&nbsp;Daisuke Katoh,&nbsp;Daisuke Yamashita,&nbsp;Hironaga Satake,&nbsp;Nobuhiro Hiramoto,&nbsp;Satoshi Yoshioka,&nbsp;Noboru Yonetani,&nbsp;Momoko Nishikori,&nbsp;Takeshi Morimoto,&nbsp;Yukihiro Imai,&nbsp;Takayuki Ishikawa\",\"doi\":\"10.1002/jha2.921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Somatic hypermutations (SHMs) in the variable region (V<sub>H</sub>) of the immunoglobulin heavy chain (IgH) gene are common in diffuse large B-cell lymphoma (DLBCL). Recently, IgH V<sub>H</sub> SHMs have become known as immunogenic neoantigens, but few studies have evaluated the prognostic impact of the frequency of V<sub>H</sub> SHMs in DLBCL. The BIOMED-2 protocol is the gold standard polymerase chain reaction (PCR) for clonality analysis in lymphoid malignancies, but can produce false negatives due to the presence of IgH V<sub>H</sub> SHMs. To overcome this problem, three primer sets were designed for the three framework regions (FR1, FR2, and FR3). We evaluated the predictive value of this PCR pattern in patients with DLBCL. To evaluate the prognostic impact of complete detection of the clonal amplifications (V<sub>H</sub>FR1–J<sub>H</sub>, V<sub>H</sub>FR2–J<sub>H</sub>, and V<sub>H</sub>FR3–J<sub>H</sub>) in the BIOMED-2 protocol, we retrospectively analyzed 301 DLBCL patients who were initially treated with anthracycline-based immunochemotherapy. Complete detection of the FR1 to FR3 primer-based IgH V<sub>H</sub> PCR patterns in the BIOMED-2 protocol was associated with low frequency of V<sub>H</sub> SHMs (<i>p</i> &lt; 0.001). Patients who were positive for all these three PCRs (<i>n</i> = 79) were significantly associated with shorter 5-year overall survival (OS; 54.2% vs. 73.2%; <i>p</i> = 0.002) and progression-free survival (PFS; 34.3% vs. 59.3%; <i>p</i> &lt; 0.001) compared to patients with other PCR patterns (<i>n</i> = 202). Specifically, the successful FR3-J<sub>H</sub> detection was associated with significantly worse OS (<i>p</i> &lt; 0.001) and PFS (<i>p</i> &lt; 0.001). PCR patterns of complete IgH rearrangement using the BIOMED-2 protocol are clinically meaningful indicators for prognostic stratification of DLBCL patients.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.921\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.921\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.921","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

免疫球蛋白重链(IgH)基因可变区(VH)的体细胞高突变(SHM)在弥漫大B细胞淋巴瘤(DLBCL)中很常见。最近,IgH VH SHMs 已成为众所周知的免疫原新抗原,但很少有研究评估 VH SHMs 频率对 DLBCL 预后的影响。BIOMED-2方案是淋巴恶性肿瘤克隆性分析的金标准聚合酶链反应(PCR),但由于存在IgH VH SHMs,可能会产生假阴性。为了克服这一问题,我们为三个框架区域(FR1、FR2 和 FR3)设计了三组引物。我们评估了这种 PCR 模式在 DLBCL 患者中的预测价值。为了评估在 BIOMED-2 方案中完全检测到克隆扩增(VHFR1-JH、VHFR2-JH 和 VHFR3-JH)对预后的影响,我们对最初接受蒽环类免疫化疗的 301 例 DLBCL 患者进行了回顾性分析。在 BIOMED-2 方案中,基于 FR1 至 FR3 引物的 IgH VH PCR 模式的完全检测与 VH SHM 的低频率相关(p <0.001)。与其他 PCR 模式的患者(n = 202)相比,这三种 PCR 均呈阳性的患者(n = 79)的 5 年总生存期(OS;54.2% vs. 73.2%;p = 0.002)和无进展生存期(PFS;34.3% vs. 59.3%;p <;0.001)明显缩短。具体来说,FR3-JH的成功检测与更差的OS(p <0.001)和PFS(p <0.001)相关。使用BIOMED-2方案检测完全IgH重排的PCR模式是对DLBCL患者进行预后分层的有临床意义的指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Complete detection of FR1 to FR3 primer-based PCR patterns of immunoglobulin heavy chain rearrangement in the BIOMED-2 protocol is associated with poor prognosis in patients with diffuse large B-cell lymphoma

Somatic hypermutations (SHMs) in the variable region (VH) of the immunoglobulin heavy chain (IgH) gene are common in diffuse large B-cell lymphoma (DLBCL). Recently, IgH VH SHMs have become known as immunogenic neoantigens, but few studies have evaluated the prognostic impact of the frequency of VH SHMs in DLBCL. The BIOMED-2 protocol is the gold standard polymerase chain reaction (PCR) for clonality analysis in lymphoid malignancies, but can produce false negatives due to the presence of IgH VH SHMs. To overcome this problem, three primer sets were designed for the three framework regions (FR1, FR2, and FR3). We evaluated the predictive value of this PCR pattern in patients with DLBCL. To evaluate the prognostic impact of complete detection of the clonal amplifications (VHFR1–JH, VHFR2–JH, and VHFR3–JH) in the BIOMED-2 protocol, we retrospectively analyzed 301 DLBCL patients who were initially treated with anthracycline-based immunochemotherapy. Complete detection of the FR1 to FR3 primer-based IgH VH PCR patterns in the BIOMED-2 protocol was associated with low frequency of VH SHMs (p < 0.001). Patients who were positive for all these three PCRs (n = 79) were significantly associated with shorter 5-year overall survival (OS; 54.2% vs. 73.2%; p = 0.002) and progression-free survival (PFS; 34.3% vs. 59.3%; p < 0.001) compared to patients with other PCR patterns (n = 202). Specifically, the successful FR3-JH detection was associated with significantly worse OS (p < 0.001) and PFS (p < 0.001). PCR patterns of complete IgH rearrangement using the BIOMED-2 protocol are clinically meaningful indicators for prognostic stratification of DLBCL patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Optimisation of the Danish national haemoglobinopathy screening programme – A prospective intervention study A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1